Skip to main content
x
Peter Warn

Dr Warn is Senior Vice President of Anti-Infective Discovery at Evotec. In this role he is the lead scientist of all contract research functions in anti-infectives and has a leading role in all internal anti-infective discovery research programs. 

Prior to his position at Evotec, Dr Warn was a founder, Director and CSO of Euprotec, a CRO focussed on providing CRO services to the anti-infective discovery industry. The company was established in 2008 and grew to 25 FTE when it was sold to Evotec as the bedrock that would become Evotec Anti-Infectives.

Before moving to Industry, Dr Warn was a senior academic at the University of Manchester where we ran a group of up to 40 scientists and PhD students focused on the pathogenesis of severe fungal disease and the pharmacodynamics of antifungal agents. Earlier in his academic career Dr Warn was a Research Fellow at the University of Oxford where he ran a research group focussed on the pathogenesis and treatment of severe malaria in children. He spent much of this time deployed to Kenya in a hyperendemic malaria zone where his team provided laboratory support for the diagnosis of severe malaria and clinical trials of novel ant-malarial drugs. Dr Warn started his career as a clinical scientist in the UK Public Health Laboratories providing diagnostics and clinical advice to hospital and general practice clinicians. He took his undergraduate and first postgraduate degrees at the University of the South West of England.
 

Selected publications:

  • Melchers MJ, Teague J, Warn P, Hansen J, Bernardini F, Wach A, Obrecht D, Dale GE, Mouton JW. (2019) Pharmacokinetics and pharmacodynamics of murepavadin in neutropenic mice models. Antimicrob Agents Chemother. In press
  • Lackner M, Birch M, Naschberger V, Grässle D, Beckmann N, Warn P, Gould J, Law D, Lass-Flörl C, Binder U. (2018) Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei. J Antimicrob Chemother. 73(11)
  • Garvey EP, Sharp AD, Warn PA, Yates CM, Schotzinger RJ. (2018) The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis. J Antimicrob Chemother. 73(10)

Supervised projects:

Associated Partner
SVP Anti Infective Discovery Evotec 
Email: peter.warn@evotec.com
Website: https://www.evotec.com/en/execute/therapeutic-areas/anti-infectives 

 


 

BACK TO ASSOCIATED PARTNERS